Adolescent and young adult (AYA) oncology in the United States

A specialty in its late adolescence

Peter Shaw, Damon R. Reed, Nicholas Yeager, Bradley Zebrack, Sharon M. Castellino, Archie Bleyer

Research output: Contribution to journalReview article

Abstract

Over the last 30 years, it has become apparent that oncology patients ages 15 to 39 have not reaped the same rewards of improved survival that we have seen in younger and older patients. As a result, in 2006 the Adolescent and Young Adult (AYA) Oncology Progress Review Group convened and examined the factors that impact the care of the 70,000 new cases per year (approximately 7% of all new cases) in the United States and published their findings. The reasons for inferior survival gains are of course multiple and include the settings in which patients are cared for, clinical trial enrollment, insurance coverage, varied treatment of sarcomas, varied treatment of acute lymphoblastic leukemia, the psychosocial impact of cancer and cancer survivorship. A new area of a yet-to-be completely defined subspecialty was born out of this meeting: AYA oncology. As a medical community we realized that these patients do not fit neatly into the pediatric nor adult world and, therefore, require a unique approach which many individuals, oncology centers, advocacy groups, and cooperative trial groups have started to address. This group of dedicated providers and advocates has made strides but there is still much work to be done on the local, national, and international level to make up for shortcomings in the medical system and improve outcomes. We review key components of AYA cancer care in 2015 that all providers should be aware of, how far we have come, where this movement is headed, and the obstacles that continue to stand in the way of better cure rates and quality of life after cure for this unique group of patients. Like an adolescent maturing into adulthood, this movement has learned from the past and is focused on moving into the future to achieve its goals.

Original languageEnglish (US)
Pages (from-to)161-169
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume37
Issue number3
DOIs
StatePublished - Apr 7 2015
Externally publishedYes

Fingerprint

Young Adult
Neoplasms
Insurance Coverage
Survival
Reward
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sarcoma
Survival Rate
Quality of Life
Clinical Trials
Pediatrics
Therapeutics

Keywords

  • acute lymphoblastic leukemia
  • AYA oncology
  • clinical trial enrollment
  • models of care
  • psychosocial
  • sarcomas
  • survivorship

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Adolescent and young adult (AYA) oncology in the United States : A specialty in its late adolescence. / Shaw, Peter; Reed, Damon R.; Yeager, Nicholas; Zebrack, Bradley; Castellino, Sharon M.; Bleyer, Archie.

In: Journal of Pediatric Hematology/Oncology, Vol. 37, No. 3, 07.04.2015, p. 161-169.

Research output: Contribution to journalReview article

Shaw, Peter ; Reed, Damon R. ; Yeager, Nicholas ; Zebrack, Bradley ; Castellino, Sharon M. ; Bleyer, Archie. / Adolescent and young adult (AYA) oncology in the United States : A specialty in its late adolescence. In: Journal of Pediatric Hematology/Oncology. 2015 ; Vol. 37, No. 3. pp. 161-169.
@article{423dab5c8f814a06a473d1eec4557980,
title = "Adolescent and young adult (AYA) oncology in the United States: A specialty in its late adolescence",
abstract = "Over the last 30 years, it has become apparent that oncology patients ages 15 to 39 have not reaped the same rewards of improved survival that we have seen in younger and older patients. As a result, in 2006 the Adolescent and Young Adult (AYA) Oncology Progress Review Group convened and examined the factors that impact the care of the 70,000 new cases per year (approximately 7{\%} of all new cases) in the United States and published their findings. The reasons for inferior survival gains are of course multiple and include the settings in which patients are cared for, clinical trial enrollment, insurance coverage, varied treatment of sarcomas, varied treatment of acute lymphoblastic leukemia, the psychosocial impact of cancer and cancer survivorship. A new area of a yet-to-be completely defined subspecialty was born out of this meeting: AYA oncology. As a medical community we realized that these patients do not fit neatly into the pediatric nor adult world and, therefore, require a unique approach which many individuals, oncology centers, advocacy groups, and cooperative trial groups have started to address. This group of dedicated providers and advocates has made strides but there is still much work to be done on the local, national, and international level to make up for shortcomings in the medical system and improve outcomes. We review key components of AYA cancer care in 2015 that all providers should be aware of, how far we have come, where this movement is headed, and the obstacles that continue to stand in the way of better cure rates and quality of life after cure for this unique group of patients. Like an adolescent maturing into adulthood, this movement has learned from the past and is focused on moving into the future to achieve its goals.",
keywords = "acute lymphoblastic leukemia, AYA oncology, clinical trial enrollment, models of care, psychosocial, sarcomas, survivorship",
author = "Peter Shaw and Reed, {Damon R.} and Nicholas Yeager and Bradley Zebrack and Castellino, {Sharon M.} and Archie Bleyer",
year = "2015",
month = "4",
day = "7",
doi = "10.1097/MPH.0000000000000318",
language = "English (US)",
volume = "37",
pages = "161--169",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Adolescent and young adult (AYA) oncology in the United States

T2 - A specialty in its late adolescence

AU - Shaw, Peter

AU - Reed, Damon R.

AU - Yeager, Nicholas

AU - Zebrack, Bradley

AU - Castellino, Sharon M.

AU - Bleyer, Archie

PY - 2015/4/7

Y1 - 2015/4/7

N2 - Over the last 30 years, it has become apparent that oncology patients ages 15 to 39 have not reaped the same rewards of improved survival that we have seen in younger and older patients. As a result, in 2006 the Adolescent and Young Adult (AYA) Oncology Progress Review Group convened and examined the factors that impact the care of the 70,000 new cases per year (approximately 7% of all new cases) in the United States and published their findings. The reasons for inferior survival gains are of course multiple and include the settings in which patients are cared for, clinical trial enrollment, insurance coverage, varied treatment of sarcomas, varied treatment of acute lymphoblastic leukemia, the psychosocial impact of cancer and cancer survivorship. A new area of a yet-to-be completely defined subspecialty was born out of this meeting: AYA oncology. As a medical community we realized that these patients do not fit neatly into the pediatric nor adult world and, therefore, require a unique approach which many individuals, oncology centers, advocacy groups, and cooperative trial groups have started to address. This group of dedicated providers and advocates has made strides but there is still much work to be done on the local, national, and international level to make up for shortcomings in the medical system and improve outcomes. We review key components of AYA cancer care in 2015 that all providers should be aware of, how far we have come, where this movement is headed, and the obstacles that continue to stand in the way of better cure rates and quality of life after cure for this unique group of patients. Like an adolescent maturing into adulthood, this movement has learned from the past and is focused on moving into the future to achieve its goals.

AB - Over the last 30 years, it has become apparent that oncology patients ages 15 to 39 have not reaped the same rewards of improved survival that we have seen in younger and older patients. As a result, in 2006 the Adolescent and Young Adult (AYA) Oncology Progress Review Group convened and examined the factors that impact the care of the 70,000 new cases per year (approximately 7% of all new cases) in the United States and published their findings. The reasons for inferior survival gains are of course multiple and include the settings in which patients are cared for, clinical trial enrollment, insurance coverage, varied treatment of sarcomas, varied treatment of acute lymphoblastic leukemia, the psychosocial impact of cancer and cancer survivorship. A new area of a yet-to-be completely defined subspecialty was born out of this meeting: AYA oncology. As a medical community we realized that these patients do not fit neatly into the pediatric nor adult world and, therefore, require a unique approach which many individuals, oncology centers, advocacy groups, and cooperative trial groups have started to address. This group of dedicated providers and advocates has made strides but there is still much work to be done on the local, national, and international level to make up for shortcomings in the medical system and improve outcomes. We review key components of AYA cancer care in 2015 that all providers should be aware of, how far we have come, where this movement is headed, and the obstacles that continue to stand in the way of better cure rates and quality of life after cure for this unique group of patients. Like an adolescent maturing into adulthood, this movement has learned from the past and is focused on moving into the future to achieve its goals.

KW - acute lymphoblastic leukemia

KW - AYA oncology

KW - clinical trial enrollment

KW - models of care

KW - psychosocial

KW - sarcomas

KW - survivorship

UR - http://www.scopus.com/inward/record.url?scp=84926347151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926347151&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000318

DO - 10.1097/MPH.0000000000000318

M3 - Review article

VL - 37

SP - 161

EP - 169

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -